鹿血晶联合白细胞介素-11治疗化疗后血小板减少症的临床观察

目的 观察中药鹿血晶联合白细胞介素-11治疗化疗后血小板减少症的疗效.方法 将60例晚期非小细胞肺癌化疗后血小板减少症患者,按数字表法随机分为两组,联合组30例给予中药鹿血晶联合白细胞介素-11,对照组30例给予白细胞介素-11,检测两组治疗后第3天、第7天及第14天血常规,观察两组血小板计数变化情况,同时评价治疗疗效.结果 治疗前及治疗后第3天两组血小板计数无显著差异(P>0.05).治疗后第7天及第14天两组血小板计数相比较,联合组显著高于对照组,差异具有统计学意义(P<0.05).另外,两组疗效相比,联合组有效率高于对照组(P<0.05).结论 中药鹿血晶联合白细胞介素-11治疗化疗后血小板减少症,能更加迅速安全地提高血小板,缩短治疗时间,最终使患者获益.

Clinical Observation of Cervus Blood Granule Combined with Recombinant Human Interleukin-11 in the Treatment of Thrombocytopenia Induced by Chemotherapy

Objective To observe the efficacy of cervus blood granule combined with recombinant human interleukin-11 in the treatment of thrombocytopenia induced by chemotherapy.Methods 60 patients with advanced non-small cell lung cancer,after chemotherapy with thrombocytopenia,were divided randomly into 2 groups by digital table method.The combined group,30 patients were treated by cervus blood granule combined with recombinant human interleukin-11.The control group,30 patients were treated by recombinant human interleukin-11 alone.All the patients were tested routine blood at the 3rd,7th and 14th day after treatment,observed the changes in platelet counts,and evaluated the treatment efficacy between the 2 groups.Results There were no significant difference in platelet count,neither before treatment nor the 3rd day after treatment,between the 2 groups(P>0.05).The platelet count of the combined group was significantly higher than the control group in the 7th and 14th day after treatment,the difference between the 2 groups had statistical significance(P<0.05).The efficacy of the combined group was higher than the control group(P<0.05).Conclusion Cervus blood granule with recombinant human interleukin-11 can more quickly and securely increase platelet count with shorter treatment time,and benefited patients.